Head to Head Review: Conexeu Sciences (NASDAQ:CNXU) versus Bioventus (NASDAQ:BVS)

Conexeu Sciences (NASDAQ:CNXU) and Bioventus (NASDAQ:BVS) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Conexeu Sciences and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
Bioventus	4.94%	29.97%	9.52%

Valuation and Earnings

This table compares Conexeu Sciences and Bioventus”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
Bioventus	$568.09 million	1.17	$22.73 million	$0.41	19.48

Bioventus has higher revenue and earnings than Conexeu Sciences.

Analyst Ratings

This is a summary of recent recommendations for Conexeu Sciences and Bioventus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0	0	0	0	0.00
Bioventus	0	1	3	1	3.00

Bioventus has a consensus target price of $14.00, suggesting a potential upside of 75.33%. Given Bioventus’ stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Conexeu Sciences.

Institutional and Insider Ownership

62.9% of Bioventus shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bioventus beats Conexeu Sciences on 10 of the 10 factors compared between the two stocks.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University’s right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company’s only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix (“ECM”) formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the “10 Minute Tissue™” concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration (“FDA”) clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.